共 50 条
- [31] A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)CANCER RESEARCH, 2024, 84 (07)Lenz, Heinz-JosefKuritzky, BenjaminThummala, AnuKendall, StephanPatel, RavindranathChandana, Sreenivasa R.Bent, Alisha H.Sherman, NancySubramanian, Ramanand ArunKabbinavar, FairoozHecht, Joel Randolph
- [32] Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKKJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Al-Batran, Salah-EddinLorenzen, SylvieSchenk, MichaelThuss-Patience, Peter C.Goekkurt, ErayHofheinz, RalfKretzschmar, AlbrechtBolling, ClausAngermeier, StefanWicki, AndreasSiebenhuener, Alexander RheinhardEigendorff, EkkehardPink, ChristinEttrich, Thomas JensSchmalenberg, HaraldWaberer, LisaTalbot, JonathanPauligk, ClaudiaGoetze, Thorsten OliverHomann, Nils
- [33] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLANCET, 2010, 376 (9742): : 687 - 697Bang, Yung-JueVan Cutsem, EricFeyereislova, AndreaChung, Hyun C.Shen, LinSawaki, AkiraLordick, FlorianOhtsu, AtsushiOmuro, YasushiSatoh, TarohAprile, GiuseppeKulikov, EvgenyHill, JulieLehle, MichaelaRuschoff, JosefKang, Yoon-Koo
- [34] Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (02) : 85 - 95Garg, Satish K.Wernicke-Panten, KarinWardecki, MarekKramer, DanielDelalande, FrancoisFranek, EdwardSadeharju, KaritaMonchamp, TravisMukherjee, BhaswatiShah, Viral N.
- [35] Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naive HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 36Su, BinGao, GuijuWang, MinLu, YanqiuLi, LinghuaChen, ChenChen, YuanyuanSong, ChuanYu, FengtingLi, YingLiu, YixinLuo, YangHe, HaolanCheng, CongXu, LixiaZhang, TongSun, LijunLiu, AnXia, WeiQin, YuanyuanZhao, QingxiaWei, HongxiaCai, WeipingChen, YaokaiZhang, FujieWu, Hao
- [36] Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infectionJOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (03): : 245 - 254Krown, SEAeppli, DBalfour, HH
- [37] Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in RussiaCLINICAL THERAPEUTICS, 2007, 29 (11) : 2374 - 2384Ushakova, OlgaSokolovskaya, VeraMorozova, AllaValeeva, FaridaZanozina, OlgaSazonova, OlgaZhadanova, ElenaStarceva, MariaKazakova, ElenaSaifullina, MarinaShapiro, IrinaTarasov, AlexanderAl-Tayar, BassamStarkova, Ninella
- [38] Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive/HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR TrialCANCER RESEARCH, 2021, 81 (04)Munzone, ElisabettaAebi, StefanJanez, Noelia MartinezGuth, UweBellet, MeritxellPistilli, BarbaraBalic, MarijaRoschitzki-Voser, HeidiRegan, Meredith M.
- [39] A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKKJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Al-Batran, Salah-EddinLorenzen, SylvieHeuer, VeraAngermeier, StefanEttrich, Thomas JensHomann, NilsHaag, Georg MartinKurreck, AnnikaStein, AlexanderHeinemann, VolkerRonellenfitsch, UlrichZander, ThomasKubicka, StefanSiebenhuener, Alexander RheinhardKopp, ChristinaPauligk, ClaudiaGoetze, Thorsten
- [40] A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKFS633/DANTE trial, a trial of AIO in collaboration with SAKKJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Al-Batran, Salah-EddinLorenzen, SylvieThuss-Patience, Peter C.Homann, NilsSchenk, MichaelLindig, UdoHeuer, VeraKretzschmar, AlbrechtGoekkurt, ErayHaag, Georg MartinRiera-Knorrenschild, JorgeBolling, ClausHofheinz, Ralf-DieterAngermeier, StefanEttrich, Thomas JensSiebenhuener, Alexander ReinhardKopp, ChristinaPauligk, ClaudiaGoetze, Thorsten Oliver